Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and sells therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its main therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is currently in a Phase 3 clinical trial for patients with advanced prostate cancer. Telix also develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy using its proprietary RADmAb-engineered antibody technology; TLX252 for treating patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for glioblastoma and multiple myeloma; TLX300 for soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. Additionally, Telix is developing BiPASS, which is in a Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. The company operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia. It has a strategic collaboration with University Hospital Essen.